⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

Marcelo V. Negrão Haniel A. Araújo Giuseppe Lamberti Alissa J. Cooper Neal S. Akhave Teng Zhou Lukas Delasos J. Kevin Hicks Mihaela Aldea Gabriele Minuti Jacobi Hines Jacqueline V. Aredo Michael J. Dennis Turja Chakrabarti Susan C. Scott Paolo Bironzo Matthias Scheffler Petros Christopoulos Albrecht Stenzinger Jonathan W. Riess So Yeon Kim Sarah B. Goldberg Mingjia Li Qi Wang Yun Qing Ying Ni Minh Truong Richard Lee Biagio Ricciuti Joao V. Alessi Jing Wang Blerina Resuli Lorenza Landi Shu-Chi Tseng Mizuki Nishino Subba R. Digumarthy Waree Rinsurongkawong Vadeerat Rinsurongkawong Ara A. Vaporciyan George R. Blumenschein Jianjun Zhang Dwight H. Owen Collin M. Blakely Giannis Mountzios Catherine A. Shu Christine M. Bestvina Marina Chiara Garassino Kristen A. Marrone Jhanelle E. Gray Sandip Pravin Patel Amy L. Cummings Heather A. Wakelee Juergen Wolf Giorgio V. Scagliotti Federico Cappuzzo Fabrice Barlési Pradnya D. Patil Leylah Drusbosky Don L. Gibbons Funda Meric‐Bernstam J. Jack Lee John V. Heymach David S. Hong Rebecca S. Heist Mark M. Awad Ferdinandos Skoulidis

View at Publisher

Ask AI

Bookmark

Share

Abstract

Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Negrão et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523ca8 https://doi.org/10.1158/2159-8290.27025400.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
2Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
3Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
4Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
5Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024

More related papers

Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024
Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024